Skip to main content
Premium Trial:

Request an Annual Quote

EPO Upholds Claims in Silence Cancer Drug Patent

Premium

Silence Therapeutics said this week that the European Patent Office has upheld an amended form of a patent covering protein kinase N beta, which is silenced with the company's phase I cancer drug Atu027.

Silence said the patent covers the use of PKN3 as a downstream target of the PI3 kinase pathway; the use of PKN3 as a downstream drug target of the PI3 kinase pathway in a screening process; the manufacture of a diagnostic agent based on use of PKN3; and the use of molecules such as siRNAs against PKN3 as a therapeutic.

In its amended form, the patent limits to metastatic cancers the diseases for which PKN3 inhibition can be used as a treatment.

"We are very pleased with the outcome of this oral opposition hearing, which has upheld the key part of our claims in this granted patent,” Silence CEO Thomas Christely said in a statement.

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.